JP7278969B2 - ドライアイ症候群を治療するための抗生物質マクロライドを送達する組成物および方法 - Google Patents

ドライアイ症候群を治療するための抗生物質マクロライドを送達する組成物および方法 Download PDF

Info

Publication number
JP7278969B2
JP7278969B2 JP2019566112A JP2019566112A JP7278969B2 JP 7278969 B2 JP7278969 B2 JP 7278969B2 JP 2019566112 A JP2019566112 A JP 2019566112A JP 2019566112 A JP2019566112 A JP 2019566112A JP 7278969 B2 JP7278969 B2 JP 7278969B2
Authority
JP
Japan
Prior art keywords
composition
active agent
days
weight
tacrolimus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019566112A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020521790A (ja
JP2020521790A5 (https=
Inventor
イシャイ・アッタール
エヤル・シートリト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eximore Ltd
Original Assignee
Eximore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eximore Ltd filed Critical Eximore Ltd
Publication of JP2020521790A publication Critical patent/JP2020521790A/ja
Publication of JP2020521790A5 publication Critical patent/JP2020521790A5/ja
Priority to JP2023077694A priority Critical patent/JP7682226B2/ja
Application granted granted Critical
Publication of JP7278969B2 publication Critical patent/JP7278969B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2019566112A 2017-05-30 2018-05-30 ドライアイ症候群を治療するための抗生物質マクロライドを送達する組成物および方法 Active JP7278969B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023077694A JP7682226B2 (ja) 2017-05-30 2023-05-10 ドライアイ症候群を治療するための抗生物質マクロライドを送達する組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762512682P 2017-05-30 2017-05-30
US62/512,682 2017-05-30
PCT/IB2018/000693 WO2018220444A2 (en) 2017-05-30 2018-05-30 Compositions and methods for treating dry eye syndrome delivering antibiotic macrolide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023077694A Division JP7682226B2 (ja) 2017-05-30 2023-05-10 ドライアイ症候群を治療するための抗生物質マクロライドを送達する組成物および方法

Publications (3)

Publication Number Publication Date
JP2020521790A JP2020521790A (ja) 2020-07-27
JP2020521790A5 JP2020521790A5 (https=) 2021-07-26
JP7278969B2 true JP7278969B2 (ja) 2023-05-22

Family

ID=64456159

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019566112A Active JP7278969B2 (ja) 2017-05-30 2018-05-30 ドライアイ症候群を治療するための抗生物質マクロライドを送達する組成物および方法
JP2023077694A Active JP7682226B2 (ja) 2017-05-30 2023-05-10 ドライアイ症候群を治療するための抗生物質マクロライドを送達する組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023077694A Active JP7682226B2 (ja) 2017-05-30 2023-05-10 ドライアイ症候群を治療するための抗生物質マクロライドを送達する組成物および方法

Country Status (7)

Country Link
US (1) US20200147055A1 (https=)
EP (1) EP3630042A4 (https=)
JP (2) JP7278969B2 (https=)
KR (1) KR20200069261A (https=)
CN (1) CN111278401B (https=)
CA (1) CA3065474A1 (https=)
WO (1) WO2018220444A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022096931A2 (en) * 2020-11-09 2022-05-12 Eximore Ltd. Punctal plugs containing micelle-encapsulated ophthalmic pharmaceuticals and methods for making thereof
WO2024069230A2 (en) * 2022-09-29 2024-04-04 Eximore Ltd. Ophthalmic compositions and methods for sustained drug release

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002543132A (ja) 1999-04-30 2002-12-17 スカンポ・アクチェンゲゼルシャフト ドライアイ処置の為のマクロライド化合物の使用
US20030018044A1 (en) 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
JP2008530128A (ja) 2005-02-09 2008-08-07 マクサイト， インコーポレイテッド 疾患または状態を処置するための液体処方物
WO2016083891A1 (en) 2014-11-25 2016-06-02 Eyal Sheetrit Compositions and methods for delivering a bio-active agent or bio-active agents

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6489335B2 (en) * 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
CA2539324A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
CN101437478A (zh) * 2004-10-04 2009-05-20 Qlt美国有限公司 聚合送递制剂的眼部送递
DE602004017477D1 (de) * 2004-11-09 2008-12-11 Novagali Pharma Sa Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential
EP2004172B1 (en) * 2006-03-31 2019-03-13 Mati Therapeutics Inc. Drug delivery structures and compositions for nasolacrimal system
UY30883A1 (es) * 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
EP2320972B1 (en) * 2008-05-08 2020-07-01 MiniPumps, LLC Implantable drug-delivery devices
EP2376019A1 (en) * 2008-12-19 2011-10-19 QLT, Inc. Substance delivering punctum implants and methods
AU2011235002B2 (en) * 2010-03-31 2016-08-11 Ocuject, Llc Device and method for intraocular drug delivery
CA2798084A1 (en) * 2010-05-17 2011-11-24 Aerie Pharmaceuticals, Inc. Drug delivery devices for delivery of ocular therapeutic agents
ES2727203T3 (es) * 2011-08-29 2019-10-14 Mati Therapeutics Inc Administración por liberación sostenida de agentes activos para tratar glaucoma e hipertensión ocular
EP2916827B1 (en) * 2012-11-08 2020-06-10 Clearside Biomedical Inc. Methods for the treatment of ocular disease in human subjects
MX364310B (es) * 2013-11-05 2019-04-22 Gustavo A Garcia Sanchez Método para preparar una formulación inmunosupresora.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002543132A (ja) 1999-04-30 2002-12-17 スカンポ・アクチェンゲゼルシャフト ドライアイ処置の為のマクロライド化合物の使用
US20030018044A1 (en) 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
JP2008530128A (ja) 2005-02-09 2008-08-07 マクサイト， インコーポレイテッド 疾患または状態を処置するための液体処方物
WO2016083891A1 (en) 2014-11-25 2016-06-02 Eyal Sheetrit Compositions and methods for delivering a bio-active agent or bio-active agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Current Eye Research，2014年，Vol.39, pp.99-102

Also Published As

Publication number Publication date
CA3065474A1 (en) 2018-12-06
JP2023113647A (ja) 2023-08-16
WO2018220444A2 (en) 2018-12-06
US20200147055A1 (en) 2020-05-14
EP3630042A2 (en) 2020-04-08
JP7682226B2 (ja) 2025-05-23
JP2020521790A (ja) 2020-07-27
CN111278401B (zh) 2023-08-15
CN111278401A (zh) 2020-06-12
EP3630042A4 (en) 2021-06-23
KR20200069261A (ko) 2020-06-16
WO2018220444A3 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
JP7682226B2 (ja) ドライアイ症候群を治療するための抗生物質マクロライドを送達する組成物および方法
JP6686023B2 (ja) 生物活性剤または生物活性剤類を送達する組成物および方法
Zhu et al. A mesoporous silica nanoparticulate/β-TCP/BG composite drug delivery system for osteoarticular tuberculosis therapy
JP4463681B2 (ja) 眼内使用のための非ポリマー親油性薬学的インプラント組成物
KR20100014629A (ko) 타크로리무스의 변형제형
JP6368242B2 (ja) ４０−ｏ−（２−ヒドロキシ）エチル−ラパマイシンを含む医薬組成物
JP2017526655A (ja) 眼において薬物徐放を達成する方法及び生体適合性組成物
US20220273674A1 (en) Extended-release drug delivery compositions
CN103189054B (zh) 含有他克莫斯有效成分的缓释微丸
EP2885045A1 (en) Process for manufacturing drug delivery formulations
EP2528600B1 (en) Dry powder pharmaceutical composition comprising tiotropium and fluticasone
WO2024069230A2 (en) Ophthalmic compositions and methods for sustained drug release
Chen et al. Composite microspheres induce the sustained release and the control of the initial release of water soluble drugs
Baker In vitro elution of analgesic medications from an absorbable gelatin sponge
WO2013109212A1 (en) Dry powder formulations comprising ciclesonide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210526

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230411

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230510

R150 Certificate of patent or registration of utility model

Ref document number: 7278969

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150